article thumbnail

FDA approves Regeneron’s Libtayo and chemotherapy combination for NSCLC

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals ’ PD-1 inhibitor Libtayo (cemiplimab-rwlc) and chemotherapy combination as the first-line treatment for advanced non-small cell lung cancer (NSCLC). Patients may receive this therapy regardless of PD-L1 expression or tumour histology.

article thumbnail

EC approves Regeneron’s Libtayo along with chemotherapy for NSCLC

Pharmaceutical Technology

The European Commission (EC) has granted approval for Regeneron Pharmaceuticals’ Libtayo (cemiplimab), along with platinum-based chemotherapy, as the first-line treatment for PD-L1 expression positive advanced non-small cell lung cancer (NSCLC) in adult patients.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Kite releases pivotal CAR T therapy Phase III study results

European Pharmaceutical Review

Historical SOC involves platinum-based salvage combination chemoimmunotherapy regimen followed by high-dose therapy (HDT) and stem cell transplant (ASCT) in patients who respond to salvage chemotherapy. According to Kite, these findings will be presented in full later this year at an upcoming scientific meeting.

article thumbnail

AstraZeneca to acquire Fusion for approximately $2bn

Pharmafile

AstraZeneca has announced that it has entered into a definitive agreement to acquire Fusion Pharmaceuticals for an approximate $2bn.

article thumbnail

Ipsen to buy biopharmaceutical company Epizyme for $247m

Pharmaceutical Technology

Ipsen has signed a definitive merger agreement to acquire all the outstanding shares of commercial-stage biopharmaceutical company Epizyme, for an initial total consideration of $247m. The transaction is focused on Epizyme’s lead asset, Tazverik (tazemetostat), a chemotherapy-free EZH2 a inhibitor. for each share. for each share.

article thumbnail

Dry Eye

RX Note

Medications Antihistamines, beta-blockers, chemotherapy, diuretics, HRT, oral contraceptives, SSRIs and TCAs may affect the quantity and composition of tears. External Links TFOS DEWS II Definition and Classification Report, 2017 Master the Maze of Artificial Tears, 2018 Artificial Tears: What Matters and Why, 2020

article thumbnail

Building a Successful Inventory Management System with Nicole Clausen

epicur

If something that is not an emergency product expires, I definitely like to evaluate it first before repurchasing the same thing again. Do we need to get a smaller container size next time? Do we need even to carry this anymore? Does it need to be discontinued or moved to an online pharmacy? What do you consider a qualified partner?